ABSTRACT Two single-nucleotide polymorphisms in the type 2 ryanodine receptor (RyR2) leading to the nonsynonymous amino acid replacements G1885E and G1886S are associated with arrhythmogenic right ventricular cardiomyopathy in patients who are carrying both of the corresponding RyR2 alleles. The functional properties of HEK293 cell lines isogenically expressing RyR2 mutants associated with arrhythmogenic right ventricular cardiomyopathy,
INTRODUCTION
The cardiac ryanodine receptor (RyR2) located in the sarcoplasmic reticulum (SR) membrane functions as a Ca 21 release channel through which, on Ca 21 -induced Ca 21 release, Ca 21 flows from the lumen of the SR into the cytoplasm and activates cardiomyocyte contraction. It thus plays a crucial role in cardiac excitation-contraction coupling (for review see Fill and Copello (1)). The large cytoplasmic domain of the functional tetrameric RyR2 channel possesses the Ca 21 binding sites for initiation of Ca 21 -induced Ca 21 release as well as binding sites for channel modulators such as FKBP12.6, calmodulin, and ATP and target sites for phosphorylation by different protein kinases such as PKA, PKC, PKG, and CaMKII (2, 3) . Three domains have been coarsely defined in RyR2, the N-terminal, the central, and the C-terminal domains, where mutations leading to cardiomyopathies including arrhythmogenic right ventricular cardiomyopathy (ARVC) and catecholaminergic polymorphic ventricular tachycardia have been located (4) . Disease-causing mutations in the N-terminal and central domains have been localized to the clamp-shaped structure of RyR2 (5-7), and these mutations alter the sensitivity of channel activation by luminal Ca 21 (8, 9) . Interaction of these two domains stabilizes the closed state of the Ca 21 release channel, and mutations in this region might weaken this interdomain interaction, leading to a decline of tight channel control, lowering of the barrier for Ca 21 release, and an increase in Ca 21 leakage from the SR (10) . Dysfunctional RyR2 has been implicated in the generation of cardiomyopathies (for a review see Thomas et al. (11) ), and diastolic Ca 21 release by a leaky cardiac Ca 21 release channel is thought to be responsible for the development of arrhythmogenesis (12) . Recently, we have identified two single-nucleotide polymorphisms (SNPs) in adjacent codons of the RYR2 gene in patients suffering from ARVC that lead to the nonsynonymous amino acid exchanges G1885E and G1886S in a composite heterozygous fashion (13) . The location affected by the mutations is part of the cardiac-specific divergent region 3 (DR3 domain) of RyR2, which is believed to be involved in regulation of the Ca 21 release channel (6) . The combination of these two polymorphisms is associated with ARVC in a subgroup of patients. RyR2 isolated from the explanted heart of such an ARVC patient shows altered channel characteristics and markedly enhanced open probability at diastolic Ca 21 concentration. Because of the heterozygous combination of the SNPs, the actual subunit composition of this leaky RyR2 channel is not known. The functional channel can be either a homotetramer encoded by either of the two alleles or a heterotetramer because of mixed expression of both alleles. Expression of G1886S would create a putative PKC phosphorylation site in RyR2, which might confer PKC-mediated modulation of the Ca 21 release channel. In this work, we investigated functional properties of defined RyR2 mutants related to the ARVC-associated alterations G1885E and G1886S: RyR2-G1885E, RyR2-G1886S, RyR2-G1886D mimicking a putatively phosphorylated Ser 1886 , and RyR2-G1885E/G1886S with both nonsynonymous amino acid exchanges in the same RyR2 subunit. The identified SNPs were introduced into mouse RYR2 cDNA, which then was used to generate stable, inducible HEK293 cell lines, each expressing a defined isogenic RyR2. The store-overload-induced calcium release (SOICR) activity of these cell lines was investigated quantitatively by single-cell Ca 21 imaging and compared with the Ca 21 release behavior of RyR2 wild-type (RyR2-WT)-expressing HEK293 cells. RyR2 protein purified from these cell lines was characterized biochemically, and the phosphorylation of RyR2-G1886S was studied using the protein kinases PKA, PKG, PKC, and CaMKII. The replacement of a glycine at the positions 1885 and 1886 of human RyR2 by an acidic residue (G1885E, G1886D) substantially enhanced the activity of the homotetrameric Ca 21 release channel. This is true, albeit to a lesser extent, also for G1886S, which is not a target of any of the protein kinases investigated. Surprisingly, the double mutant, G1885E/G1886S, was nearly completely inactive. This indicates that these two positions in the RyR2 primary sequence mark a sensitive spot in the DR3 domain that is involved in the control of the Ca 21 release properties of the channel.
EXPERIMENTAL PROCEDURES Materials
Monoclonal RyR2 antibody (34c) was obtained from Acris Antibodies (Hiddenhausen, Germany) FITC-labeled antimouse secondary antibody and polyclonal anti-FKBP antibody were from Alexis (Lausen, Switzerland), and peroxidase coupled antimouse and antirabbit secondary antibodies were from MBI Fermentas (Madison, WI). Soybean phosphatidylcholine was purchased from Avanti Polar Lipids (Alabaster, AL), CHAPS and other reagents were from Sigma (St. Louis, MO). Activated EAH Sepharose, N-ethyl-N9(3-dimethylamino-propyl) carbodiimid (EDC), ECL kit and hyperfilm were obtained from Amersham (Little Chalfont, Bucks, UK). Talon affinity matrix was from Clontech (Mountainview, CA) and Restore Western Blot Stripping Buffer from Pierce (Rockford, IL). Ca 21 fluorescence indicators fura-2 AM and fluo-3 AM as well as hygromycin and tetracycline were purchased from Invitrogen (Carlsbad, CA).
Site-directed mutagenesis and DNA transfection
To generate the RyR2 mutants G1885E, G1886S, G1886D, and the double mutant G1885E/G1886S, the corresponding SNPs were introduced into the full-length mouse RyR2 cDNA using the overlap extension PCR method as described by Ho et al. (14) . It is of note that the sequence of the human codons affected by the SNPs, 5653-5658, is homologous to the mouse RyR2 cDNA codon sequence 5650-5655; however, in this article, instead of the changed nucleotide sequence, the resulting amino acid exchange corresponding to the human sequence is used. The sequences of the primers used for mutagenesis were as follows: RyR2-G1885E sense, 59-GCCAAAGA-GGGTAAAAGGCCC-39, and antisense, 59-TTTACCCTCTTTGGCTTCT-TCT T-39; RyR2-G1886S sense, 59-AAAGGGAGTAAAAGGCCCAAG-39, and antisense, 59-CCTTT TACTCCCTTTGGCTTC-39; RyR2-G1886D sense, 59-AAAGGGGATAAAAGGCCCAAG-39, and antisense, 59-CCTTTTATC-CCCTTTGGCTTC-39; RyR2-G1885E/G1886S sense, 59-GCC AAAGAGA-GTAAAAGGCCCAAG-39, and antisense, 59-CCTTTTACTCTCTTTGGC-TTCTT C-39. The sequences of the flanking (outer) primers were, sense, 59-AGTGAACGCCAAGGCTG G-39, and antisense, 59-AACGTACTG-AAGTAATATGGACTT-39. The RyR2 cDNA fragments containing the mutations were cloned back into the original position of the RyR2 cDNA sequence to replace the wild-type sequence. After confirmation of the mutations by DNA sequencing, the mutated RyR2 cDNAs were used for transfection of HEK293 cells using the Ca 21 phosphate precipitation method as described in detail by Li and Chen (15 ] o , the relative number of oscillating cells, cumulatively summed up over the whole observed frequency bandwidth, will approach 1 with increasing oscillation frequency. This cumulative relative oscillation frequency distribution (CROFD) is given by
ðqð f ÞÞ ¼ 1:
(1)
For all [Ca 21 ] o used, the CROFD obtained can well be described by the empirical function
with q ¼ q 0 for f ¼ 0 and q ¼ 1 for f ) 1=g: The characteristic parameters q 0 ; g; and n were obtained from fits to the CROFD measured at [Ca 21 ] o of 0 to 1 mM. According to the experimental results obtained, g and q 0 are [Ca 21 ] o -dependent parameters that can be approximated by the functions
the parameters of which were determined by fits to the measured data. Generation and purification of phosphorylation state-and site-specific anti-RyR2 antibodies
The individually designed polyclonal antisera and the synthetic peptides corresponding to the sequences of the mouse RyR2 were obtained from NeoMPS (Strasbourg, France). The following phosphopeptides and nonphosphopeptides were constructed: H 1 -GGAKGS(PO 3 )KRPK-AHX-Y-OH (pSer-1886) and H 1 -GGAKGSKRPK-AHX-Y-OH (Ser-1886). These are unique among the known phosphopeptide sequences, and they are typical for RyR2 according to a BLASTP2.2.5 database search. To generate antibodies to the two peptides, two rabbits each were immunized with the above peptides covalently coupled to ovalbumin. IgG fractions were obtained after ammonium sulfate precipitation according to Javois (16) and subjected to affinity chromatography over carbodiimid-activated EAH Sepharose 4B (Amersham Biosciences) coupled with phosphopeptides and nonphosphopeptides according to manufacturer's instructions. The columns were reused several times and stored in water at 4°C. To obtain the phosphospecific antibodies and to eliminate the nonphospho-and nonspecific antibodies, the IgG fraction was first applied to the nonphosphopeptide affinity column. The breakthrough containing phosphopeptide antibodies obtained by washing the column with BBS buffer was applied to the phosphopeptide affinity column. Phosphopeptide antibodies were eluted with 0.1 M glycine, 0.5 M NaCl, pH 2.7, into tubes containing NaOH to neutralize the pH. Nonphosphopeptide antibodies were purified analogously by first applying the IgG fraction to a column prebound with the phosphopeptide. The resulting flowthrough was then applied to the nonphosphopeptide affinity column. Immunoreactivity and -specificity of the affinity-purified phosphoand nonphosphopeptide antibodies were determined by means of ELISA. Preimmune sera showed no immunoreactivity.
Human recombinant FKBP12.6
The plasmid construct for the expression of the N-terminal polyhistidinetagged FKBP12.6 fusion protein was generated using the TOPO-TA cloning kit (Invitrogen). As template for amplification, a human brain total cDNA (Clontech) was used with the following primers: sense, 59-ATGGGCGTG-GAGATCGAGACCATC-39, and antisense, 59-TCACTCTAAGTTGAG-CAG CTCCACGTC-39. After amplification, the PCR product was ligated into the expression vector pCRT7/NT TOPO (Invitrogen), and the sequence of the cloned construct was confirmed by DNA sequencing. After transformation of chemical competent BL21(DE3) E. coli, protein overexpression was induced by 0.4 mM isopropyl-b-thiogalactopyranoside. The recombinant polyhistidine-tagged FKBP12.6 fusion protein was obtained from the supernatant of the cell homogenate by means of affinity chromatography columns (Protino Ni-Ted kit, Macherey-Nagel, Düren, Germany).
Preparation of cell lysate, solubilization, and enrichment of the expressed RyR2 and ryanodine binding assay Cell lysates were obtained from stable, inducible HEK293 cells grown for various durations after induction by 1 mg/ml tetracycline as described in detail by Kong et al. (17) . Recombinant RyR2 proteins were further enriched either by sucrose density gradient centrifugation (7-25% w/v) for 16 h at 100,000 3 g (13) or by affinity chromatography using Talon Affinity matrix (Clontech) prebound with purified 300 mg His-tagged FKBP12.6 fusion protein for 18 h at 4°C. After sedimentation and washing with PBS buffer, the sediment containing the RyR2-FKBP12.6 complex-bound beads was used directly as substrate in phosphorylation assays. The binding of RyR2 to the FKBP12.6-loaded matrix was confirmed by SDS-PAGE and Western blotting after elution of the RyR2-FKBP12.6 complex from the beads by SDS sample buffer. [ 3 H]Ryanodine binding assays were carried out with different RyR2 variants as described by Jiang et al. (9) .
Phosphorylation of Ser 1886 in RyR2-G1886S by various protein kinases
Recombinant RyR2 obtained in different ways was used as a substrate for protein kinases previously activity-optimized with model peptides and proteins, respectively, according to the instructions provided by the suppliers. PKA catalytic subunit was a generous gift from Dr. Friedrich Herberg, Universität Kassel, Germany. Recombinant PKG was purchased from Alexis (Lausen, Switzerland), catalytic subunit of native PKC of rat brain was obtained from Calbiochem (La Jolla, CA), and recombinant CaMKII was from New England Biolabs (Ipswich, MA). RyR2 in the following states of purity were used: RyR2 in cell lysate, enriched by sucrose gradient centrifugation, or purified by affinity chromatography over FKBP12.6-bound Talon Sepharose beads. Phosphorylation by catalytic subunit of PKA was carried out in a buffer containing 10 mM MOPS, pH 7.0, 200 mM KCl, 1.5 mM DTT, 0.5 mM [g-32 P]ATP, and 50 nM ocadaic acid.
Statistical evaluation
Mean values are presented as mean 6 SE, and statistical comparison of data corresponding to the different RyR2 was carried out using one-way ANOVA with Tukey's posttest. An error probability p , 0.05 was considered significant and is indicated where applicable.
RESULTS
Construction and generation of stable, inducible HEK293 cell lines expressing RyR2-WT, RyR2-G1885E, RyR2-G1886S, RyR2-G1886D, and RyR2-G1885E/G1886S
We have previously shown that a composite heterozygous SNP combination leading to the nonsynonymous exchanges G1885E and G1886S in the human RyR2 1), is associated with ARVC, 2), leads to a substantially increased diastolic open probability of RyR2 from a terminally failing heart of such a patient, and 3), may contain a PKC phosphorylation site created by one of the mutations, G1886S (13) . The actual tetrameric subunit combination(s) of the functional RyR2 in human hearts of this RyR2 genotype is not known. Two possible compositions resulting from homozygous combinations are given by RyR2-G1885E and RyR2-G1886S, respectively, which were recombinantly generated. The latter represents the homotetramer with the suggested putative PKC phosphorylation site. Stable, inducible HEK293 cell lines expressing the ARVCrelated RyR2 mutants G1885E and G1886S were generated according to the method of Jiang et al. (8) . Additionally, a cell line that stably expresses RyR2-G1886D, mimicking a constitutively phosphorylated Ser
1886
, and a further one with both mutations in a single RyR2 subunit (RyR2-G1885E/G1886S) were established. The functional properties of these RyR2 variants were studied by measuring the SOICR activity of the RyR2-expressing HEK293 cells and by phosphorylation assays using purified RyR2-G1886S as a substrate for the protein kinases PKC, PKA, PKG, and CaMKII.
The expression of the variant RyR2 proteins in HEK293 cell lines was confirmed by immunofluorescent staining (Fig.   1, A-F) and Western blotting (Fig. 1 G) using monoclonal RyR2 antibody. This antibody detected a high-molecularweight band in the HEK293 cell lines expressing RyR2 (Fig.  1, B-G) but not in the parental cells transfected with the control vector DNA (Fig. 1 A) .
Biochemical characterization of the different RyR2 mutants
To determine whether the expressed RyR2-WT, RyR2-G1885E, RyR2-G1886S, RyR2-G1886D, and RyR2-G1885E/ G1886S, respectively, function as Ca 21 release channels, we measured intracellular Ca 21 release in HEK293 cells expressing the various RyR2 forms using the fluorescent Ca 21 indicator dye fluo-3 acetoxymethyl ester. As shown in Fig. 2 A, all RyR2-expressing HEK293 cell lines displayed comparable Ca 21 transients in response to repeated stimulation by caffeine, a well-known activator of RyR2. The normalized caffeine dose-response curves obtained from the traces shown in Fig. 2 A were similar for RyR2-WT, RyR2-G1885E, RyR2-G1886S, and RyR2-G1886D, with halfmaximum responses in the range of 0.11-0.20 mM caffeine (Fig. 2 B) . For RyR2-G1885E/G1886S the half-maximum response was observed at 0.40 mM caffeine. Because the caffeine activation procedure was the same for all cell lines, these data suggest that the doubly mutated RyR2 is relatively less sensitive to caffeine than the other RyR2 variants ( p , 0.001). The Ca 21 -dependent [ 3 H]ryanodine binding to the different RyR2 (Fig. 2 D) reaches half-saturation at about the same Ca 21 concentration but rises with a markedly reduced Ca 21 cooperativity in case of RyR2-G1885E/G1886S compared with the other RyR2 variants (p , 0.001). On the other hand, the well-known suppression (18) of the caffeineinduced Ca 21 release by ryanodine (Fig. 2 C, b and c) after it has gained access to the open state of the channel induced by caffeine (Fig. 2 C, a) is well preserved for all the expressed RyR2 variants. These data indicate comparable, wild-typelike channel function for the mutants RyR2-G1885E, RyR2-G1886S, and RyR2-G1886D and altered channel properties for the double mutant RyR2-G1885E/G1886S.
Phosphorylation of Ser 1886 in RyR2-G1886S
The phosphorylation of Ser 1886 , which is a putative PKC phosphorylation site in the RyR2 mutant G1886S (13), was investigated using recombinant RyR2-G1886S protein of different purification states as a substrate for PKC and other protein kinases, PKA, PKG, and CaMKII, known to phosphorylate RyR2 (for review see Meissner (3) and Xiao et al. (19) ). The substrate was presented in three different purification grades: RyR2-G1886S in crude cell lysate (Fig. 3 A) , RyR2-G1886S bound to FKBP12.6-coupled Sepharose beads (Fig. 3 B) , and RyR2-G1886S highly enriched by sucrose density centrifugation (Fig. 3 C) . All tested kinases phosphorylate the mutant channel protein (row 4). Phosphorylation of RyR2 at Ser 1886 by these kinases was studied by means of sequence-specific antibodies that selectively recognize either the phosphorylated (phosphopeptide antibodies) or the nonphosphorylated serine residue (nonphosphopeptide antibodies). The phosphopeptide antibodies did not identify a phosphorylated serine residue (row 2), although sufficient amounts of substrate protein were available for all kinases (rows 3 and 4). Accordingly, nonphosphorylated Ser 1886 was detected by nonphosphopeptide antibodies in this mutant RyR2 presented in different degrees of purity (row 1). Thus, the mutation-created Ser 1886 is unlikely to be a target of any of the tested kinases.
SOICR in HEK293 cells expressing different RyR2 mutants
Single-cell Ca 21 imaging experiments with the stable, inducible HEK293 cell lines were carried out to assess their SOICR properties as described by Jiang et al. (8) . These RyR2 expressing HEK293 cells are all sensitive to caffeine applied at the end of an experiment (Fig. 4 , left and right panels). They also, with the notable exception of HEK cells expressing RyR2-G1885E/G1886S, readily developed SOICR activity when perfused with increasing [Ca 21 ] o . This leads to a time domain filled with Ca 21 transients before the final activation by 5 mM caffeine (Fig. 4, middle panel) . In the experiment shown in Fig. 4 , ;40-70% of the caffeinesensitive HEK293 cells expressing RyR2-WT (41%), RyR2-G1885E (68%), RyR2-G1886S (49%), and RyR2-G1886D (59%), respectively, exhibited substantial SOICR (Fig. 4,  A-D) . In contrast, of a comparable number of 264 caffeineresponsive HEK293 cells expressing RyR2-G1885E/G1886S, only three (1%) showed significant Ca 21 release activity (Fig. 4 E) . This markedly different SOICR behavior is summarized in Fig. 5 on the basis of four independent experiments. The number of cells showing SOICR compared with the total number of caffeine-responsive cells rises sigmoidally with increasing [Ca 21 ] o for all RyR2 variants expressed (Fig. 5 A) . So did the average number of Ca 21 transients per caffeine-responsive cell (Fig. 5 B) as well as the FIGURE 2 Fluo-3 fluorescence of HEK293 cells (A-C) expressing RyR2-WT, RyR2-G1886S, RyR2-G1886D, RyR2-G1885E, and RyR2-G1885E/ G1886S, respectively, in response to caffeine (A, B, C) and ryanodine (C) and Ca (Fig. 5 C) . Because of the very low number of oscillatory active HEK293 cells expressing RyR2-G1885E/G1886S, reliable fits to the data could not easily be obtained in this case. Nevertheless, it is obvious that, on average, these cells are much less Ca 21 oscillating (Fig. 5, A (Fig. 5 C) than the other RyR2-expressing cell lines. The data shown in Fig. 5 also suggest more subtle differences among these latter RyR2 variants, especially for RyR2-G1885E and -G1886D compared with RyR2-WT and -G1886S. A detailed analysis of the Ca 21 -oscillating behavior of individual cells of the different RyR2-expressing cell lines reveals essentially the same results (data not shown). The comparison of the [Ca 21 ] o -dependent SOICR activity of these cells isogenically expressing a defined RyR2 yields the following sequence of RyR2 channel activity:
In case of the double mutant RyR2-G1885E/G1886S, SOICR is nearly completely abolished. 21 -imaging experiments, the Ca 21 transients induced by 5 mM caffeine at the end of an experiment were compared among the different cell lines (Fig. 6 A) . The amplitude of this transient, which reflects the Ca 21 loading of the store after a preceding history of SOICR, is similar for RyR2-WT, RyR2-G1886S, RyR2-G1886D, and RyR2-G1885E but strongly enhanced for RyR2-G1885E/G1886S (Fig. 6 A, 21 -oscillating HEK293 cells expressing RyR2-G1885E/G1886S (Fig. 6 A,  gray bars) . The amplitudes of the SOICR events during the Ca 21 perfusion period were very similar for HEK293 cells expressing RyR2-WT, RyR2-G1886S, RyR2-G1886D, and RyR2-G1885E, respectively (Fig. 6 B) 
DISCUSSION
The amino acid exchanges G1885E and G1886S investigated here, which are caused by ARVC-associated SNPs (13), are FIGURE 3 Phosphorylation of Ser 1886 in RyR2-G1886S by various protein kinases. Three different types of RyR2-G1886S preparation were used as substrate for PKA, PKC, PKG, and CaMKII as indicated in the figure: (A) RyR2 in HEK293 cell lysate, (B) RyR2 immobilized to FKBP12.6-coupled beads, and (C) RyR2 enriched by sucrose density gradient centrifugation. After separation by SDS-PAGE, the proteins were immunoblotted with antibody against RyR2 (row 3), sequence-specific antibodies against a Ser 1886 -containing peptide reflecting the potential RyR2 phosphorylation site (nonphosphopeptide antibody, row 1), and corresponding antibodies against a Ser1886(PO 3 )-containing peptide (phosphopeptide antibody, row 2). Autoradiographs (row 4) demonstrate the phosphorylation of RyR2-G1886S by all of the protein kinases applied, but Ser 1886 is no substrate of one of these tested kinases (compare rows 1 and 2). located in the divergent region 3 of RyR2 that is specific for cardiac muscle. This DR3 domain comprises residues 1852-1890 of RyR2 (6) and has been mapped to domain 9 in the clamp structure of RyR2 (20) . The two glycine residues affected by the SNPs lay adjacent to the FKBP12.6 binding site, which recently has been assigned to the residues 1636-1937 (21) . Because of the heterozygous combination of the two SNPs associated with ARVC in a subgroup of patients (13) , carriers of this RyR2 genotype are not expressing wildtype RyR2 but RyR2 subunits that contain the amino acid exchange G1885E or G1886S in either a sole or combined fashion. In the study presented here, we have investigated homotetrameric RyR2 composed of subunits with either Glu 1885 or Ser 1886 in the DR3 domain, which reflect the former of the two possibilities mentioned before. A coex- pression of both RyR2 mutants in a single cell, which would
